CELLULAR ONCOLOGY is an esteemed open access journal published by SPRINGER since 2004, specializing in the dynamic field of oncological research. With its ISSN 2211-3428 and E-ISSN 2211-3436, this journal plays a pivotal role in disseminating cutting-edge findings and innovative methodologies that address cancer at the cellular level. The journal has consistently achieved high-impact recognition, currently holding a Q2 rating in Cancer Research and Q1 rankings in Medicine (miscellaneous), Molecular Medicine, and Oncology as of 2023. Furthermore, it ranks 56th in oncology medicine and 48th in cancer research according to Scopus, placing it firmly within the top echelons of its field. Published in the Netherlands, with an aim to connect scientists, clinicians, and practitioners worldwide, CELLULAR ONCOLOGY fosters a collaborative environment for researchers to share insights, enhance understanding, and advance treatments. The journal’s open access model ensures that ground-breaking research is freely available, facilitating greater visibility and impact within the scientific community and beyond.

ONCOLOGY RESEARCH, published by TECH SCIENCE PRESS, is a vital academic journal dedicated to the rapidly evolving field of oncology. With its ISSN 0965-0407 and E-ISSN 1555-3906, the journal serves as a key resource for researchers, clinicians, and academicians committed to advancing cancer research and treatment strategies. Operating without an Open Access model, ONCOLOGY RESEARCH provides high-quality, peer-reviewed articles that cover diverse topics within cancer research, medicine, and oncology, with its 2023 Scopus ranking placing it in the Q3 quartile. The journal's commitment to facilitating rigorous scientific discourse is evident in its historical breadth, with a publishing history dating back to 1992. ONCOLOGY RESEARCH is not only significant for the academic community but also plays a critical role in fostering new insights and approaches in the fight against cancer, making it a must-read for those involved in this critical area of study.

Chinese Journal of Cancer Research, published by Chinese Journal Cancer Research Co, is a pivotal platform for disseminating significant findings in the field of oncology. Since its inception in 1988, the journal has provided a comprehensive forum for cancer research, featuring peer-reviewed articles that cover various aspects of cancer biology, prevention, diagnosis, and treatment. Although the journal's coverage is currently discontinued in Scopus and holds an HIndex that has not been specified, it is ranked in the 65th percentile in Medicine - Oncology and the 48th percentile in Biochemistry, Genetics and Molecular Biology - Cancer Research. This reflects its commitment to maintaining quality and relevance in the rapidly evolving field of cancer research. Researchers, professionals, and students are encouraged to explore its rich archive of studies and breakthroughs to enhance their understanding and further their research. For access, the publication remains instrumental for those invested in advancing the global fight against cancer.

CANCER INVESTIGATION is a distinguished peer-reviewed journal published by Taylor & Francis Inc, dedicated to the advancing field of cancer research and oncology. With an ISSN of 0735-7907 and E-ISSN of 1532-4192, this journal has been a pivotal resource for professionals and researchers since its inception in 1983, continually contributing to the evolving landscape of cancer investigation until its convergence in 2024. CANCER INVESTIGATION boasts noteworthy rankings in 2023, including Q3 in Cancer Research and Q2 in Medicine (miscellaneous), highlighting its relevance and impact in these critical areas. The journal's commitment to disseminating innovative research and comprehensive reviews makes it an essential platform for those engaged in cancer studies and related disciplines. While currently not available as an open-access publication, CANCER INVESTIGATION remains an invaluable tool for understanding the complexities of cancer, offering insights that drive scientific advancements and improve patient outcomes.

Recent Patents on Anti-Cancer Drug Discovery, published by Bentham Science Publishers Ltd, is an esteemed peer-reviewed journal specializing in the innovative intersection of pharmaceutical science and oncology. With an ISSN of 1574-8928 and an E-ISSN of 2212-3970, this journal aims to provide a comprehensive platform for the dissemination of recent developments in anti-cancer drug discovery, addressing critical issues and breakthroughs that influence cancer research and treatment. The journal spans from 2006 to 2024 and is indexed in several prestigious databases, showcasing its relevance with a Q3 ranking in key categories such as Cancer Research and Drug Discovery as of 2023. Its status of being open access reflects a commitment to making valuable scientific findings widely available, promoting collaboration and advancement in the field. With a dedicated focus on advancing knowledge in cancer therapeutics, the journal serves as a vital resource for researchers, healthcare professionals, and students aiming to contribute to the fight against cancer.

Cancer Immunology Immunotherapy, published by Springer, stands as a premier journal in the fields of cancer research and immunology, holding a prestigious Q1 ranking across multiple categories, including Oncology and Medicine as of 2023. With an ISSN of 0340-7004 and an E-ISSN of 1432-0851, this journal has been a pivotal platform for groundbreaking research since its inception in 1976, continuing to provide insight into the complex interactions between the immune system and cancer. The journal's scope encompasses a wide array of topics, including novel therapeutic strategies, immunological mechanisms, and translational science aimed at advancing treatment outcomes for cancer patients. Renowned for its rigorous peer-review process and high impact factor, it attracts contributions from leading experts and researchers around the globe, positioning itself among the top-tier publications with Scopus rankings that reflect its vital role in advancing the field. Access options are generally subscription-based, ensuring a comprehensive resource for professionals and academics seeking to deepen their understanding and make meaningful contributions to cancer immunotherapy.

Oncologie is a distinguished academic journal published by WALTER DE GRUYTER GMBH, focusing on the dynamic and vital field of oncology. Established in 1999 and continuously published until 2024, this journal provides a platform for high-quality research and advancements in cancer treatment, prevention, and diagnosis. With an ISSN of 1292-3818 and an E-ISSN of 1765-2839, it is indexed in various databases, contributing to its growing visibility. Although categorized in the Q3 quartile for oncology research as of 2023, Oncologie offers essential insights and fosters scholarly dialogue among researchers, professionals, and students interested in oncology. Its unique contributions aim to bridge the gap between theoretical frameworks and clinical applications, making it a valuable resource for those seeking to advance their knowledge and expertise in cancer research.

Journal of Cancer Metastasis and Treatment, published by OAE PUBLISHING INC, stands as a vital resource in the field of oncology, focusing on advancements and research pertaining to cancer metastasis and treatment methodologies. With an ISSN of 2394-4722 and an E-ISSN of 2454-2857, this journal aims to serve as a comprehensive platform for sharing innovative research, critical analyses, and novel findings from 2019 through 2024. As indexed in Scopus, it holds a notable Q3 ranking within its category, positioned at 240/404 and within the 40th percentile, thus reflecting its growing significance in the scientific community. Though currently not open access, the journal aspires to improve accessibility to pivotal oncology research, making it an essential tool for researchers, clinicians, and students keen on unraveling the complexities of cancer treatment and metastasis. Its commitment to promoting high-quality studies plays a crucial role in the ongoing quest to enhance patient care and outcomes in cancer treatment.

Advances in Cancer Biology-Metastasis is an emerging journal published by Elsevier, aimed at advancing our understanding of the complexities of cancer biology, with a specific focus on the mechanisms and pathways related to metastasis. With an E-ISSN of 2667-3940, this journal offers a platform for researchers, professionals, and students in the fields of Cancer Research and Cell Biology to disseminate innovative findings and discuss novel therapeutic approaches. Though currently classified in the Q4 quartile across both Cancer Research and Cell Biology categories, the journal aspires to enhance its impact through rigorous peer review and high-quality publication. Positioned to cover the years from 2021 to 2024, it seeks to bridge gaps in foundational knowledge and promote collaborative research efforts that could pivot the current understanding of cancer metastasis. Researchers are encouraged to take advantage of this platform to advocate for advancements in cancer biology, making significant contributions that can influence both academic and clinical practices.

CURRENT CANCER DRUG TARGETS is a prominent academic journal published by Bentham Science Publishers Ltd, focusing on the critical intersection of cancer research and innovative drug development. Since its inception in 2001, this journal has offered a platform for the dissemination of cutting-edge research aimed at advancing targeted cancer therapies, contributing significantly to the fields of Cancer Research, Drug Discovery, Oncology, and Pharmacology. With a respectable impact factor and consistent ranking in its respective categories, including Q2 in Drug Discovery and Pharmacology, it positions itself as an invaluable resource for researchers, clinicians, and students alike. CURRENT CANCER DRUG TARGETS is dedicated to enhancing our understanding of novel therapeutic targets and methods, thereby fostering a collaborative environment for knowledge exchange in the ever-evolving landscape of cancer treatment.